2-Methyl-5-(1-phenylpiperidin-4-yl)-1,3,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Methyl-5-(1-phenylpiperidin-4-yl)-1,3,4-oxadiazole
• 英文别名: 2-methyl-5-(1-phenylpiperidin-4-yl)-1,3,4-oxadiazole
• 化学式: C₁₄H₁₇N₃O
• 分子量: 243.3
• InChiKey: JICFSJRFIDTBLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE
  申请人：Cadila Healthcare Limited

  公开号：EP3030561B1

  公开（公告）日：2017-01-11
• [EN] N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE<br/>[FR] N-CYANOMÉTHYLAMIDES COMME INHIBITEURS DE LA JANUS KINASE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2015019365A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds of general formula (1) that are inhibitors of Janus Kinase (JAK), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound of the invention inhibits JAK1 and/or JAK2 and/or JAK3 sub families. The present invention also provides methods for the production of the compounds of the invention, pharmaceutical compositions comprising the compounds of the invention, their tautomeric forms, and their pharmaceutically acceptable salts.